Avantor Inc (AVTR) Stock Analysis

Verdict: WATCH (do not buy)

Q2 guidance hike marks the end of biopharma destocking, but the 45% monthly surge prices in the recovery, leaving little margin for error.

Investment score: 58/100

Analysis as of

Is Avantor Inc stock worth reviewing? AI model thesis

Avantor has successfully pivoted from a multi-quarter decline, evidenced by the Q2 2026 guidance raise and the return of its VWR segment to organic growth. However, after a 44.8% 30-day rally, the stock has hit major analyst price targets, and its high debt-to-equity profile remains a bottleneck for further valuation expansion.

7-factor investment score

Avantor Inc opportunities and risks

What speaks for AVTR

What speaks against AVTR

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
AVTRn/a1.4x466.7x31.8%-8.8%3.0%
TEMn/a5.4xn/a71.8%-17.8%-2.4%
RVTY54.1x4.4x19.6x51.4%8.3%3.9%
CRLn/a2.8x48.8x31.9%-4.6%3.5%
TECH101.5x9.3x44.0x65.0%9.0%2.4%
BRKRn/a2.8x37.4x45.6%-0.3%0.5%
Peer mediann/a4.4x37.4x51.4%-0.3%2.4%

Frequently asked questions about Avantor Inc (AVTR)

Is AVTR stock a good investment?

The cached TradeMates AI model rates Avantor Inc as WATCH (do not buy) with an investment score of 58/100. Avantor has successfully pivoted from a multi-quarter decline, evidenced by the Q2 2026 guidance raise and the return of its VWR segment to organic growth. However, after a 44.8% 30-day rally, the stock has hit major analyst price targets, and its high debt-to-equity profile remains a bottleneck for further valuation expansion. This is algorithmic model output, not personal investment advice.

Is AVTR stock a buy?

The TradeMates model verdict for AVTR is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.